



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

11 Aug 2020 (#36)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Upcoming Deadlines

- [Global Infectious Disease Research Training](#) D71 28 October 2020
- [Mobile Health: Technology and Outcomes in LMICs](#) 24 September 2020; AIDS deadline 3 December 2020
- [Emerging Global Leader Award](#) 4 November 2020
- [Global Brain Disorders Research](#) 6 November 2020
- [Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs](#) 12 November 2020
- [Chronic, Noncommunicable Diseases and Disorders Research Training \(NCD-Lifespan\)](#) D43 13 November 2020
- [Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#) 18 November 2020

Important Notices

- [Changes to Notice of Award \(NOA\) on 1 October 2020](#) Grant recipients will see a new layout of Page One of the NOA. This new layout is part of HHS's Reinvent Grants Management initiative to standardize the NoA across various HHS systems. The first page will present key award information at a glance. For more information, please see Guide Notice [NOT-OD-20-155](#).
- [Podcast Invention Reporting and Patent Protections for Grantees](#): So your supported research led to a nifty new invention, one that might even be patentable. What do you do next? Does NIH need to know about the invention resulting from the awarded grant? What patent protections and rights do you have? Ever heard of Bayh-Dole or iEdison?
- Save the Date: [Fall 2020 NIH Virtual Seminar on Program Funding and Grants Administration!](#)
- The Human Frontier Science Program (HFSP) is accepting applications for the [HFSP postdoctoral fellowship program](#), which supports proposals for frontier, potentially transformative research in the life sciences. Applications for high-risk projects are particularly encouraged. NIH is an HFSP partner. **Application initiation deadline (to obtain a reference number): August 13, 2020.** Application deadline: August 27, 2020

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notices of Special Interest

- [NOT-AG-20-038](#): Notice of Special Interest: Sex and Gender Differences in Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD)
- [NOT-AG-20-040](#): Notice of Special Interest: Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimers Disease and Related Dementias (AD/ADRD)
- [NOT-AT-20-016](#): Notice of Special Interest (NOSI): Discovery of Analgesic Natural Products through the NINDS IGNITE Program
- [NOT-NS-20-095](#): Notice of Special Interest (NOSI): Platform Trials of Thrombectomy in Acute Stroke Treatment
- [NOT-OD-20-152](#): Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool

Funding Opportunities

1. NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-270](#)

Type: R34

Application Due Date: September 14, 2020; January 12, 2021; May 12, 2021; September 14, 2021; January 12, 2022; May 13, 2022; September 14, 2022; January 13, 2023; May 12, 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<https://www.niaid.nih.gov/research/role>).

Budget: Application budgets are limited to \$150,000 direct costs. The scope of the proposed project should determine the project period. The maximum period is one year.

2. Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-294](#)

Type: U01

Application Due Date: November 12, 2020; April 9, 2021; November 9, 2021; April 7, 2022; November 9, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support the maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. Systematic Characterization of Genomic Variation on Genome Function and Phenotype (UM1 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-043](#)

Type: UM1

Application Due Date: November 4, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA seeks applications to experimentally correlate genomic variants with their effects on genomic function. This will be accomplished by performing systematic perturbation; collecting data on the effects of non-coding and protein-coding genomic variation on molecular, cellular, and organismal phenotypes; generating a catalog of these variant effects; and assisting in a group predictive modeling effort using the data. This will also be accomplished by enabling others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Centers funded through this initiative will become part of the Impact of Genomic Variation on Function (IGVF) Consortium. As members of this Consortium, functional characterization centers will be expected to work closely with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease through the coordination of data collection strategies and analyses.

Budget: NHGRI intends to commit up to \$7.5 M total costs in FY21 and up to \$15 M total costs per year in FY22- FY25 to fund 7-10 awards. Application budgets must reflect the actual needs of the proposed project. In FY21 application budgets are limited to \$700,000 direct costs and \$1.4M direct costs per year in FY22-FY25. The maximum project period is 5 years.

4. Defining Genomic Influence on Gene Network Regulation (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-044](#)

Type: U01

Application Due Date: November 4, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA seeks applications for research projects to explore the effects of genomic variation on phenotypes at the network level. Research projects supported through this FOA will measure changes in the activity of genes and regulatory elements during biological transitions and use generalizable analytical approaches to understand network-level relationships among genomic variation, functional elements, genes, and phenotypes related to human health and disease. Funded projects will also enable others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Projects funded through this initiative will become part of the Impact of Genomic Variation on Function Consortium. As members of this Consortium, network projects will be expected to work with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease.

Budget: NHGRI intends to commit \$7M total costs per year in FY21-FY25 to fund 5-7 awards. The actual amount is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets must reflect the actual needs of the proposed project. Application budgets are limited to \$900K direct costs per year. The maximum project period is 5 years.

5. Single-cell Profiling of Regulatory Element and Gene Activity in Relationship to Genome Function (UM1 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-045](#)

Type: UM1

Application Due Date: November 4, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to establish Mapping Centers that will generate single-cell, multi-omic maps of genes and regulatory elements in the human and mouse genomes. This will be accomplished through use of high-throughput state-of-the-art methods to profile biochemical features characteristic of genomic elements while preserving information about biological and/or spatial context. As a group, Mapping Centers will be expected to pursue studies that will provide a range of data types that will best enable the association of gene and regulatory element activity with specific cell fates and states. Mapping Centers will also enable others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Centers funded through this initiative will become part of the Impact of Genomic Variation on Function (IGVF) Consortium. As members of this consortium, Mapping Centers will be expected to work closely with one another and other consortium components to accelerate understanding of how genomic variation impacts human health and disease through the coordination of data collection strategies and analyses.

Budget: NHGRI intends to commit \$4M total costs in FY21, and \$8M total costs per year in FY22-FY25 to fund 3-5 centers. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets must reflect the actual needs of the proposed project. In FY21 application budgets are limited to \$900,000 direct costs and \$1.8M direct costs per year in FY22-FY25. The maximum project period is 5 years.

6. Developing Predictive Models of the Impact of Genomic Variation on Function (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-047](#)

Type: U01

Application Due Date: November 4, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA seeks applications for Predictive Modeling Projects that will develop and apply innovative computational models to predict the impact of genomic variation on genome function and/or phenotype and generate a catalog of variant effects. Projects will also enable others to perform related research by sharing approaches and standards and by identifying methodological strengths and weaknesses. Projects funded through this initiative will become part of the Impact of Genomic Variation on Function Consortium. As members of this Consortium, predictive modeling projects will be expected to work closely with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease.

Budget: NHGRI intends to commit \$2.5M total costs in FY21 and \$5M total costs per year in FY22-FY25 to fund 6-8 awards. The actual amount is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets must reflect the actual needs of the proposed project. Application budgets are limited to \$275K direct costs per year in FY21 and \$550K direct costs per year in FY22-FY25. The maximum project period is 5 years.

7. BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-20-600](#)

Type: R24

Application Due Date: July 14, 2021, July 14, 2022, and July 14, 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the research community to incorporate tools that allow users to analyze and visualize the data, but the creation of such tools is not part of this FOA. The data archives will use appropriate standards to describe the data, but the creation of such standards is not part of this FOA. A goal of this program is to advance research by creating a community resource data archive with appropriate standards and summary information that is broadly available and accessible to the research community for furthering research.

Budget: Issuing IC and partner components intend to commit an estimated total of \$4 million to fund 3-4 awards at each receipt date. It is expected that costs will be substantially higher after the first year of these awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

8. Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-NS-21-006](#)

Type: R01

Application Due Date: October 27, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement invites research on the mechanism(s) by which abnormal proteins spread throughout the nervous systems of patients with Frontotemporal Dementia and/or Lewy Body Dementia. Applications that move beyond a focus on one mechanism of spread to consider how spreading might proceed in the context of multiple proteinopathies, multiple cell/circuit types, and multiple pathways are of particular interest.

Budget: NINDS intends to commit \$2,250,000 in FY 2021 to fund 3-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

9. Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-OD-20-014](#)

Type: U01

Application Due Date: September 15, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for 2019 Novel Coronavirus (COVID-19). This emergency FOA from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. To achieve the goal of this FOA, the proposed project needs to be milestone driven and carried out by a multidisciplinary team with complementary expertise. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Budget: NIH intends to fund an estimate of 10 awards, corresponding to a total of \$10M, for fiscal years 2020, and 2021. Application budgets are limited to \$300,000 in direct costs annually. The maximum project period is 2 years.

10. Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-OD-20-016](#)

Type: R01

Application Due Date: September 30, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Budget: NIH intends to commit \$7M in FY 2021 to fund 6-8 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 3 years.

11. Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kids) (R61/R33 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-OD-20-023](#)

Type: R61/R33

Application Due Date: September 30, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Budget: The NIH OD intends to commit an estimated total of \$5,000,000 in fiscal year 2021 to fund approximately 5-6 awards. Application budgets are limited to \$500,000 in direct costs per year in the R61 phase and \$1,000,000 in direct costs per year in the R33 phase. All F&A costs are excluded from this limit. Requested budgets should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period for an application submitted in response to this FOA cannot exceed 4 years. Applicants may request up to two years of support for the R61 phase, and up to two years of support for the R33 phase.

**Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University**
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

**Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University**
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105